171 related articles for article (PubMed ID: 37937640)
1. Mutant RB1 enhances therapeutic efficacy of PARPis in lung adenocarcinoma by triggering the cGAS/STING pathway.
Dong Q; Yu T; Chen B; Liu M; Sun X; Cao H; Liu K; Xu H; Wang Y; Zhuang S; Jin Z; Liang H; Hui Y; Gu Y
JCI Insight; 2023 Nov; 8(21):. PubMed ID: 37937640
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Chabanon RM; Muirhead G; Krastev DB; Adam J; Morel D; Garrido M; Lamb A; Hénon C; Dorvault N; Rouanne M; Marlow R; Bajrami I; Cardeñosa ML; Konde A; Besse B; Ashworth A; Pettitt SJ; Haider S; Marabelle A; Tutt AN; Soria JC; Lord CJ; Postel-Vinay S
J Clin Invest; 2019 Mar; 129(3):1211-1228. PubMed ID: 30589644
[TBL] [Abstract][Full Text] [Related]
3. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer.
Shen D; Luo J; Chen L; Ma W; Mao X; Zhang Y; Zheng J; Wang Y; Wan J; Wang S; Ouyang J; Yi H; Liu D; Huang W; Zhang W; Liu Z; McLeod HL; He Y
Cancer Lett; 2022 Dec; 550():215919. PubMed ID: 36116741
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vulnerability to PARP1,2 inhibition in RB1-mutant osteosarcoma.
Zoumpoulidou G; Alvarez-Mendoza C; Mancusi C; Ahmed RM; Denman M; Steele CD; Tarabichi M; Roy E; Davies LR; Manji J; Cristalli C; Scotlandi K; Pillay N; Strauss SJ; Mittnacht S
Nat Commun; 2021 Dec; 12(1):7064. PubMed ID: 34862364
[TBL] [Abstract][Full Text] [Related]
5. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
6. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
[TBL] [Abstract][Full Text] [Related]
7. RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.
Jiang X; Li Y; Zhang N; Gao Y; Han L; Li S; Li J; Liu X; Gong Y; Xie C
Cell Biosci; 2021 Apr; 11(1):74. PubMed ID: 33858512
[TBL] [Abstract][Full Text] [Related]
8. PARP Inhibitors in Ovarian Cancer: A Review.
O'Malley DM; Krivak TC; Kabil N; Munley J; Moore KN
Target Oncol; 2023 Jul; 18(4):471-503. PubMed ID: 37268756
[TBL] [Abstract][Full Text] [Related]
9. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Niki T; Takahashi H; Sakuma Y
Biochem Biophys Res Commun; 2018 Jun; 501(1):253-258. PubMed ID: 29727601
[TBL] [Abstract][Full Text] [Related]
10. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
11. Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J; Wei B; Feng J; Wu X; Chang Y; Wang Y; Yang X; Zhang H; Han S; Zhang C; Zheng J; Groen HJM; van den Berg A; Ma J; Li H; Guo Y
Front Endocrinol (Lausanne); 2022; 13():1006480. PubMed ID: 36583000
[TBL] [Abstract][Full Text] [Related]
12. TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway.
Cheng G; Wu J; Ji M; Hu W; Wu C; Jiang J
BMC Cancer; 2023 Sep; 23(1):825. PubMed ID: 37667220
[TBL] [Abstract][Full Text] [Related]
13. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Liu B; Li L; Yang G; Geng C; Luo Y; Wu W; Manyam GC; Korentzelos D; Park S; Tang Z; Wu C; Dong Z; Sigouros M; Sboner A; Beltran H; Chen Y; Corn PG; Tetzlaff MT; Troncoso P; Broom B; Thompson TC
Clin Cancer Res; 2019 Nov; 25(22):6839-6851. PubMed ID: 31439587
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitor plus radiotherapy reshape the immune suppressive microenvironment and potentiate the efficacy of immune checkpoint inhibitors in tumors with IDH1 mutation.
Hu X; Zhao M; Bai M; Xue Z; Wang F; Zhu Z; Yu J; Yue J
Cancer Lett; 2024 Apr; 586():216676. PubMed ID: 38278469
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D
Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496
[TBL] [Abstract][Full Text] [Related]
17. Targeted Inhibition of the E3 Ligase SCF
Zhao H; Iqbal NJ; Sukrithan V; Nicholas C; Xue Y; Yu C; Locker J; Zou J; Schwartz EL; Zhu L
Cancer Res; 2020 Jun; 80(11):2355-2367. PubMed ID: 32265224
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.
Pros E; Saigi M; Alameda D; Gomez-Mariano G; Martinez-Delgado B; Alburquerque-Bejar JJ; Carretero J; Tonda R; Esteve-Codina A; Catala I; Palmero R; Jove M; Lazaro C; Patiño-Garcia A; Gil-Bazo I; Verdura S; Teulé A; Torres-Lanzas J; Sidransky D; Reguart N; Pio R; Juan-Vidal O; Nadal E; Felip E; Montuenga LM; Sanchez-Cespedes M
Ann Oncol; 2020 Feb; 31(2):274-282. PubMed ID: 31959344
[TBL] [Abstract][Full Text] [Related]
19. Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer.
Bhateja P; Chiu M; Wildey G; Lipka MB; Fu P; Yang MCL; Ardeshir-Larijani F; Sharma N; Dowlati A
Cancer Med; 2019 Apr; 8(4):1459-1466. PubMed ID: 30773851
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
